MedTrace Logo

Metformin as Adjunct Therapy in Depression-obesity Comorbidity: Clinical and Genetic Evaluation

NCT07654179 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-08-07

No results posted yet for this study

Summary

The patients with depression and obesity will receive add-on metformin with antidepressant therapy, which may result in greater improvement in depressive symptoms and BMI reduction compared to antidepressant monotherapy. NEGR1/RPL31P12 gene polymorphisms may influence the comparative efficacy of antidepressant monotherapy versus combination therapy (antidepressant + metformin) in Pakistani patients. Patients with certain variants may respond better or worse to antidepressants and may have different weight outcomes.

Conditions

Interventions

DRUG

Metformin

Tab 500-2000 mg/day (500 mg BD to 1000 mg BD)

DRUG

Antidepressant Therapy

Sertraline 50 mg/day or Duloxetine 60 mg/day or Bupropion XL 150-300 mg/day

Sponsors & Collaborators

  • Riphah International University

    lead OTHER

Principal Investigators

  • Afifa,Siddique, PhD Scholar, MBBS, M.Phil · Islamic International Medical College, Riphah International University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-17
Primary Completion
2027-06-11
Completion
2027-06-11

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07654179 on ClinicalTrials.gov